The broader implication is a potential shift in dental care toward regenerative medicine, with the possibility of tooth regrowth becoming a routine option by 2030 if trials continue to show positive results.

The approach blocks USAG-1 to lift inhibition on bone morphogenetic protein signaling, which can reactivate dormant tooth buds and trigger new tooth development.

A Japanese research team began the first human trials in 2026 for a drug that regrows teeth by inhibiting USAG-1, potentially enabling natural regeneration instead of implants or dentures.

In May 2026, Japan launched the first-ever human trials for a USAG-1–inhibiting drug designed to reactivate dormant tooth buds and promote natural tooth regrowth.

If Phase 1 succeeds, Phase 2 would enroll children aged 2–7 with congenital anodontia, a rare genetic condition, addressing partial tooth agenesis affecting up to about 10% of people globally.

Phase 2 would target young children with congenital anodontia, a condition where teeth fail to form, in a trial if Phase 1 shows positive safety and early efficacy signals.

Challenges include ensuring regrown teeth align properly, integrate with blood vessels and nerves, and prove long-term durability; pricing and accessibility will influence adoption.

Long-term adoption will hinge on real-world durability and cost, with early estimates around $11,000 per tooth and questions of access.

The potential global impact extends beyond Japan given millions missing teeth in the U.S., suggesting a shift toward regeneration over implants or dentures.

Animal studies—starting with mice and extending to ferrets and dogs—show that blocking USAG-1 and boosting BMP signaling can induce tooth formation with manageable safety.

Earlier animal research demonstrated that USAG-1 blockade can stimulate new teeth, with functional outcomes and no major adverse effects in multiple species.

If successful, natural tooth regeneration could reduce the need for implants and dentures, lowering long-term costs and changing standard dental care.